413 related articles for article (PubMed ID: 23481183)
1. Using macrophage activation to augment immunotherapy of established tumours.
Fridlender ZG; Jassar A; Mishalian I; Wang LC; Kapoor V; Cheng G; Sun J; Singhal S; Levy L; Albelda SM
Br J Cancer; 2013 Apr; 108(6):1288-97. PubMed ID: 23481183
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
3. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
[TBL] [Abstract][Full Text] [Related]
4. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
Downey CM; Aghaei M; Schwendener RA; Jirik FR
PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
[TBL] [Abstract][Full Text] [Related]
5. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
[TBL] [Abstract][Full Text] [Related]
6. Dioscin elicits anti-tumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer.
Cui L; Yang G; Ye J; Yao Y; Lu G; Chen J; Fang L; Lu S; Zhou J
J Cell Mol Med; 2020 Aug; 24(16):9217-9230. PubMed ID: 32618105
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Cuccarese MF; Dubach JM; Pfirschke C; Engblom C; Garris C; Miller MA; Pittet MJ; Weissleder R
Nat Commun; 2017 Feb; 8():14293. PubMed ID: 28176769
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
[TBL] [Abstract][Full Text] [Related]
12. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
14. Macrophage targeting: opening new possibilities for cancer immunotherapy.
Cassetta L; Kitamura T
Immunology; 2018 Nov; 155(3):285-293. PubMed ID: 29963704
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
16. Hirsutella sinensis Inhibits Lewis Lung Cancer via Tumor Microenvironment Effector T Cells in Mice.
Fu H; Jin L; Shao X; Li Y; Chen F; Shou Z; Tang X; Ji B; Shou Q
Am J Chin Med; 2018; 46(4):911-922. PubMed ID: 29754506
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Administration of
Wang Y; An EK; Kim SJ; You S; Jin JO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638944
[TBL] [Abstract][Full Text] [Related]
19. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway.
Xiao X; Li Y; Wang Y; Zhang Y; Chen J; Liu W; Tang J; Yue F; Yang J
Int Immunopharmacol; 2022 Feb; 103():108427. PubMed ID: 34922249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
